Austrália - inglês - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - itraconazole, quantity: 50 mg - capsule - excipient ingredients: silicon dioxide; magnesium stearate; sodium starch glycollate type a; hypromellose phthalate; gelatin; brilliant blue fcf; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - superficial mycoses: lozanoc is indicated, if external treatment is not effective or not appropriate, for the treatment of the following fungal infections: dermatomycoses (e.g. tinea corporis, tinea cruris, tinea pedis, tinea manus, tinea unguium) and pityriasis versicolor. systemic mycoses: lozanoc is indicated for the treatment of systemic mycoses, such as candidiasis, aspergillosis, and histoplasmosis. consideration should be given to official guidance on the appropriate use of antimycotic agents, and to the discussion of the pharmacodynamic properties (see pharmacology).

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - itraconazole, quantity: 50 mg - capsule - excipient ingredients: sodium starch glycollate type a; titanium dioxide; brilliant blue fcf; hypromellose phthalate; silicon dioxide; magnesium stearate; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - superficial mycoses: lozanoc is indicated, if external treatment is not effective or not appropriate, for the treatment of the following fungal infections: dermatomycoses (e.g. tinea corporis, tinea cruris, tinea pedis, tinea manus, tinea unguium) and pityriasis versicolor. systemic mycoses: lozanoc is indicated for the treatment of systemic mycoses, such as candidiasis, aspergillosis, and histoplasmosis. consideration should be given to official guidance on the appropriate use of antimycotic agents, and to the discussion of the pharmacodynamic properties (see pharmacology).

Canadá - inglês - Health Canada

teva canada limited - clavulanic acid (potassium clavulanate); amoxicillin (amoxicillin trihydrate) - tablet - 125mg; 500mg - clavulanic acid (potassium clavulanate) 125mg; amoxicillin (amoxicillin trihydrate) 500mg - aminopenicillins

Canadá - inglês - Health Canada

teva canada limited - amoxicillin (amoxicillin trihydrate); clavulanic acid (clavulanate potassium) - suspension - 125mg; 31.25mg - amoxicillin (amoxicillin trihydrate) 125mg; clavulanic acid (clavulanate potassium) 31.25mg - aminopenicillins

Canadá - inglês - Health Canada

teva canada limited - amoxicillin (amoxicillin trihydrate); clavulanic acid (clavulanate potassium) - suspension - 250mg; 62.5mg - amoxicillin (amoxicillin trihydrate) 250mg; clavulanic acid (clavulanate potassium) 62.5mg - aminopenicillins

Canadá - inglês - Health Canada

teva canada limited - clavulanic acid (clavulanate potassium); amoxicillin (amoxicillin trihydrate) - tablet - 125mg; 875mg - clavulanic acid (clavulanate potassium) 125mg; amoxicillin (amoxicillin trihydrate) 875mg - aminopenicillins

Canadá - inglês - Health Canada

pro doc limitee - amoxicillin (amoxicillin trihydrate); clavulanic acid (potassium clavulanate) - tablet - 500mg; 125mg - amoxicillin (amoxicillin trihydrate) 500mg; clavulanic acid (potassium clavulanate) 125mg - aminopenicillins

Canadá - inglês - Health Canada

pro doc limitee - amoxicillin (amoxicillin trihydrate); clavulanic acid (potassium clavulanate) - tablet - 875mg; 125mg - amoxicillin (amoxicillin trihydrate) 875mg; clavulanic acid (potassium clavulanate) 125mg - aminopenicillins

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - vancomycin hydrochloride, quantity: 1.026 g (equivalent: vancomycin, qty 1 g) - injection, powder for - excipient ingredients: nitrogen; hydrochloric acid; water for injections - vancomycin hydrochloride for intravenous infusion is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial medicine, including the penicillins and cephalosporins. vancomycin is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly. vancomycin is effective alone or in combination with an aminoglycoside for endocarditis caused by strep. viridans or strep. bovis. for endocarditis caused by enterococci (eg enterococcus faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by staph. epidermidis or diphtheroids. the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures. specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - vancomycin hydrochloride, quantity: 513 mg (equivalent: vancomycin, qty 500 mg) - injection, powder for - excipient ingredients: hydrochloric acid; water for injections; nitrogen - vancomycin hydrochloride for intravenous infusion is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial medicine, including the penicillins and cephalosporins. vancomycin is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly. vancomycin is effective alone or in combination with an aminoglycoside for endocarditis caused by strep. viridans or strep. bovis. for endocarditis caused by enterococci (eg enterococcus faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by staph. epidermidis or diphtheroids. the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures. specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.